In bid to ex­tend cash run­way, Cara to lay off work­ers, dis­con­tin­ue PhI­II pro­gram in chron­ic kid­ney dis­ease

Last year
People
Pharma

Io­n­is touts PhI­II suc­cess for rare dis­ease drug amid com­pa­ny's push to com­mer­cial­ize drugs in­de­pen­dent­ly

Last year
R&D

Sagimet’s pos­i­tive PhI­Ib NASH da­ta; FDA lifts hold on Phar­varis IND; Di­anthus rais­es $230M

Last year
News Briefing

Lack­lus­ter da­ta on Alzheimer's drugs lead to end of Roche-AC Im­mune part­ner­ship

Last year
Deals
R&D

Trodelvy fails PhI­II lung can­cer study in blow to Gilead’s ADC ex­pan­sion plans

Last year
R&D

Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Last year
Financing
Startups

Lu­naD­NA, a con­nec­tor of pa­tients and phar­ma­ceu­ti­cals, to shut­ter

Last year
Diagnostics

Co­herus sells San­doz its Lu­cen­tis biosim­i­lar for $170M to fo­cus on on­col­o­gy as­sets 

Last year
Deals
Pharma

Ap­n­imed hires Pfiz­er, Bio­haven vet­er­an as chief com­mer­cial of­fi­cer

Last year
People
Pharma

Hi­ber­na­tion re­search could lead to new weight loss med­i­cines — could it al­so help as­tro­nauts in space?

Last year
Deals
R&D

Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

Last year
Financing
Deals

Bay­er rolls out big changes; 2024's biotech IPO queue; Dupix­en­t's 'next big thing'; 23and­Me's strug­gle with dual ...

Last year
Weekly

J&J wins full ap­proval for blad­der can­cer drug

Last year
Pharma
FDA+

As­traZeneca's Imfinzi com­bo ex­tends PFS in liv­er can­cer; No­var­tis shares new de­tails about Lu­tather­a's PhI­II

Last year
R&D

De­San­tis, John­son raise flags around Covid boost­ers as FDA main­tains that they're safe and ef­fec­tive

Last year
Pharma
FDA+

As­traZeneca's rare blood dis­or­der pill ap­proved in Japan

Last year
Pharma
FDA+

For­mer Ther­a­nos CEO Eliz­a­beth Holmes is banned from fed­er­al health pro­grams for al­most a cen­tu­ry

Last year
People

Cannes Li­ons taps Edel­man, Dentsu ex­ecs to lead the phar­ma, health and well­ness ju­ries

Last year
Pharma
Marketing

As­traZeneca, Boehringer In­gel­heim, GSK de­fend patent list­ings as Klobuchar amps up pres­sure

Last year
Pharma
FDA+

Lund­beck en­cour­ages mi­graine pa­tients to ‘Say Yep’ to its IV-in­fused med in lat­est cam­paign

Last year
Pharma
Marketing

Af­ter Bris­tol My­ers pulls out of col­lab­o­ra­tion, Ike­na On­col­o­gy lays off 35% of staff and trims can­cer pipeline

Last year
People
R&D

PMV to cut 30% of its work­force; Edge­wise, Es­pe­ri­on an­nounce pub­lic of­fer­ings

Last year
News Briefing

New­ly hope­ful, bio­phar­ma still faces an un­cer­tain 2024

Last year
Financing
Pharma

CAR NK ther­a­py looks durable in a small tri­al, giv­ing in­sight in­to large Take­da study

Last year
R&D
Cell/Gene Tx
First page Previous page 214215216217218219220 Next page Last page
A service from the Financial Times